---
schema_version: "secwatch.filing_event.v1"
accession: "0001728117-23-000050"
form_type: "8-K"
ticker: "GOSS"
cik: "0001728117"
company_name: "Gossamer Bio, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:33:04.412316+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Gossamer Bio Q1 net loss $49.2M; advancing seralutinib to Phase 3 in PAH

## Summary
- Net loss of $49.2M ($0.52 per share) for Q1 2023 vs. $57.8M ($0.76) in Q1 2022.
- Cash, equivalents and marketable securities of $201.9M as of March 31, 2023; expected to fund operations through at least 12 months.
- Phase 3 registrational trial of seralutinib in PAH planned for 3Q23; FDA and EMA feedback on key design elements received.
- Operational restructuring: headcount reduced by over 25%; all other clinical/preclinical programs terminated.
- Initial open-label extension data from TORREY study expected mid-2023.

## SEC filing metadata
- accession: 0001728117-23-000050
- form_type: 8-K
- ticker: GOSS
- cik: 0001728117
- company_name: Gossamer Bio, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728117/000172811723000050/0001728117-23-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728117/000172811723000050/goss-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728117-23-000050
- JSON: https://secwatch.observer/filing/0001728117-23-000050.json
- Plain text: https://secwatch.observer/filing/0001728117-23-000050.txt

## Key facts
- Earnings Releases
  Gossamer Bio, Inc. reported the quarter ended March 31, 2023 results: net income Net loss for the quarter ended March 31, 2023, was $49.2 million, or $0.52 per share.
  - Period: the quarter ended March 31, 2023
  - Net income: Net loss for the quarter ended March 31, 2023, was $49.2 million, or $0.52 per share
  - Result: reported results
  source text: On May 9, 2023, Gossamer Bio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728117/000172811723000050/0001728117-23-000050-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.